{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T21:41:01Z","timestamp":1788903661622,"version":"build-2803163510"},"reference-count":23,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Clin Nucl Med"],"published-print":{"date-parts":[[2022,4]]},"abstract":"<jats:sec>\n            <jats:title>Introduction and Aim<\/jats:title>\n            <jats:p>Cancer-associated fibroblasts, which are densely found in tumor tissue, express high levels of fibroblast activation protein (FAP), and FAP inhibitors (FAPIs) labeled with radionuclides can be used in the diagnosis and treatment of cancer. In this study, the role of <jats:sup>68<\/jats:sup>Ga-DOTA-FAPI-04 PET\/CT in imaging of primary, metastatic, and recurrent cancers was investigated.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patients and Methods<\/jats:title>\n            <jats:p>A total of 42 patients (16 females, 26 males; mean age, 58.5 years; range, 31\u201384 years) with 22 different types of malignant diseases were included in the study. <jats:sup>68<\/jats:sup>Ga-DOTA-FAPI-04 PET\/CT imaging was performed 1 to 7 days after <jats:sup>18<\/jats:sup>F-FDG PET\/CT. Pathological uptake levels in primary tumoral lesions, lymph nodes, skeletal system, liver, peritoneal surfaces, and other body parts were compared between 2 PET\/CTs. In addition, physiological uptake levels of <jats:sup>18<\/jats:sup>F-FDG and <jats:sup>68<\/jats:sup>Ga-FAPI were defined measuring the liver, thoracic aorta, gluteal muscle activities, and uterus activity in female patients.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Of the 42 patients in the study group, 33 patients were included for staging, 8 patients for restaging, and 1 patient for evaluation of treatment response. <jats:sup>68<\/jats:sup>Ga-DOTA-FAPI-04 PET\/CT showed intense uptake in 94.2% of primary tumoral lesions. In patients with multiple myeloma, <jats:sup>18<\/jats:sup>F-FDG uptake in the bone marrow was significantly higher than <jats:sup>68<\/jats:sup>Ga-FAPI uptake, whereas in gastric signet ring cell tumors, <jats:sup>68<\/jats:sup>Ga-FAPI uptake was found to be significantly higher than <jats:sup>18<\/jats:sup>F-FDG uptake. It was observed that <jats:sup>68<\/jats:sup>Ga-DOTA-FAPI-04 PET\/CT detected bone, liver, and peritoneum metastases with higher sensitivity and accuracy compared <jats:sup>18<\/jats:sup>F-FDG PET\/CT.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>The preliminary findings of this study showed that <jats:sup>68<\/jats:sup>Ga-DOTA-FAPI-04 PET\/CT can contribute to the diagnostic process in solid tumors. Especially in malignancies with mild uptake on <jats:sup>18<\/jats:sup>F-FDG PET\/CT, it stands out in diagnosis, staging, and restaging. It is also predicted that FAPI molecules can be used for radionuclide therapy in patients with metastatic disease and unresponsive to other treatments showing intense uptake on <jats:sup>68<\/jats:sup>Ga-DOTA-FAPI-04 PET\/CT.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/rlu.0000000000004073","type":"journal-article","created":{"date-parts":[[2022,1,27]],"date-time":"2022-01-27T21:04:36Z","timestamp":1643317476000},"page":"e333-e339","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":82,"title":["Tumor Imaging With 68Ga-DOTA-FAPI-04 PET\/CT"],"prefix":"10.1097","volume":"47","author":[{"given":"Tevfik Fikret","family":"\u00c7ermik","sequence":"first","affiliation":[{"name":"Clinic of Nuclear Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nurhan","family":"Erg\u00fcl","sequence":"additional","affiliation":[{"name":"Clinic of Nuclear Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bur\u00e7ak","family":"Y\u0131lmaz","sequence":"additional","affiliation":[{"name":"Clinic of Nuclear Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00fcldem","family":"Mercano\u011flu","sequence":"additional","affiliation":[{"name":"Faculty of Pharmacy, Istanbul Training and Research Hospital, University of Health Sciences, Istanbul, Turkey."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2022,1,25]]},"reference":[{"key":"bib1-20250621","doi-asserted-by":"crossref","first-page":"801","DOI":"10.2967\/jnumed.119.227967","article-title":"68Ga-FAPI PET\/CT: tracer uptake in 28 different kinds of cancer","volume":"60","year":"2019","journal-title":"J Nucl Med"},{"key":"bib2-20250621","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1007\/s00259-020-04769-z","article-title":"Comparison of [68Ga]Ga-DOTA-FAPI-04 and [18F] FDG PET\/CT for the diagnosis of primary and metastatic lesions in patients with various types of cancer","volume":"47","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib3-20250621","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.2967\/jnumed.118.210435","article-title":"A tumor-imaging method targeting cancer-associated fibroblasts","volume":"59","year":"2018","journal-title":"J Nucl Med"},{"key":"bib4-20250621","doi-asserted-by":"crossref","first-page":"386","DOI":"10.2967\/jnumed.118.215913","article-title":"68Ga-FAPI PET\/CT: biodistribution and preliminary dosimetry estimate of 2 DOTA-containing FAP-targeting agents in patients with various cancers","volume":"60","year":"2019","journal-title":"J Nucl Med"},{"key":"bib5-20250621","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.2967\/jnumed.118.210443","article-title":"Development of quinoline-based theranostic ligands for the targeting of fibroblast activation protein","volume":"59","year":"2018","journal-title":"J Nucl Med"},{"key":"bib6-20250621","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s00259-020-04940-6","article-title":"Usefulness of [68Ga]Ga-DOTA-FAPI-04 PET\/CT in patients presenting with inconclusive [18F]FDG PET\/CT findings","volume":"48","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib7-20250621","doi-asserted-by":"crossref","first-page":"e141","DOI":"10.1097\/RLU.0000000000003489","article-title":"Fibroblast activation protein inhibitor PET\/CT: a promising molecular imaging tool","volume":"46","year":"2021","journal-title":"Clin Nucl Med"},{"key":"bib8-20250621","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1007\/s00259-020-04990-w","article-title":"A theranostic approach of [68Ga]Ga-DOTA.SA.FAPi PET\/CT-guided [177Lu]Lu-DOTA.SA.FAPi radionuclide therapy in an end-stage breast cancer patient: new frontier in targeted radionuclide therapy","volume":"48","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib9-20250621","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1148\/radiol.2020203275","article-title":"Comparison of 68Ga-FAPI and 18F-FDG uptake in gastric, duodenal, and colorectal cancers","volume":"298","year":"2021","journal-title":"Radiology"},{"key":"bib10-20250621","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1007\/s00259-020-05132-y","article-title":"Biodistribution, pharmacokinetics, dosimetry of [68Ga]Ga-DOTA.SA.FAPi, and the head-to-head comparison with [18F]F-FDG PET\/CT in patients with various cancers","volume":"48","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib11-20250621","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1007\/s00259-020-04882-z","article-title":"Fibroblast imaging of hepatic carcinoma with 68Ga-FAPI-04 PET\/CT: a pilot study in patients with suspected hepatic nodules","volume":"48","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib12-20250621","doi-asserted-by":"crossref","first-page":"737827","DOI":"10.3389\/fonc.2021.737827","article-title":"Comparison of the relative diagnostic performance of [68Ga]Ga-DOTA-FAPI-04 and [18F]FDG PET\/CT for the detection of bone metastasis in patients with different cancers","volume":"11","year":"2021","journal-title":"Front Oncol"},{"key":"bib13-20250621","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1007\/s00259-020-05070-9","article-title":"Comparison of PET imaging of activated fibroblasts and 18F-FDG for diagnosis of primary hepatic tumours: a prospective pilot study","volume":"48","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib14-20250621","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1097\/RLU.0000000000003056","article-title":"Comparison of 68Ga-FAPI and 18F-FDG PET\/CT in a patient with cholangiocellular carcinoma: a case report","volume":"45","year":"2020","journal-title":"Clin Nucl Med"},{"key":"bib15-20250621","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1007\/s00259-020-05095-0","article-title":"Imaging fibroblast activation protein in liver cancer: a single-center post hoc retrospective analysis to compare [68Ga]Ga-FAPI-04 PET\/CT versus MRI and [18F]-FDG PET\/CT","volume":"48","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib16-20250621","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1007\/s00259-020-05146-6","article-title":"Role of [68Ga]Ga-DOTA-FAPI-04 PET\/CT in the evaluation of peritoneal carcinomatosis and comparison with [18F]-FDG PET\/CT","volume":"48","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib17-20250621","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.2967\/jnumed.119.237016","article-title":"The role of 68Ga-FAPI PET\/CT for patients with malignancies of the lower gastrointestinal tract: first clinical experience","volume":"61","year":"2020","journal-title":"J Nucl Med"},{"key":"bib18-20250621","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1007\/s00259-020-04941-5","article-title":"[18F]FDG and [68Ga]Ga-DOTA-FAPI-04 PET\/CT in the evaluation of tuberculous lesions","volume":"48","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib19-20250621","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.1007\/s00259-021-05194-6","article-title":"Non-malignant findings of focal 68Ga-FAPI-04 uptake in pancreas","volume":"48","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib20-20250621","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1097\/RLU.0000000000002914","article-title":"Intense FAPI uptake in inflammation may mask the tumor activity of pancreatic cancer in 68Ga-FAPI PET\/CT","volume":"45","year":"2020","journal-title":"Clin Nucl Med"},{"key":"bib21-20250621","doi-asserted-by":"crossref","first-page":"779","DOI":"10.2967\/jnumed.120.253062","article-title":"Impact of 68Ga-FAPI PET\/CT imaging on the therapeutic management of primary and recurrent pancreatic ductal adenocarcinomas","volume":"62","year":"2021","journal-title":"J Nucl Med"},{"key":"bib22-20250621","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1007\/s00259-020-04859-y","article-title":"Fibroblast activation protein inhibitor (FAPI) PET for diagnostics and advanced targeted radiotherapy in head and neck cancers","volume":"47","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib23-20250621","doi-asserted-by":"crossref","first-page":"563","DOI":"10.2967\/jnumed.119.233122","article-title":"Theranostics targeting fibroblast activation protein in the tumor stroma: 64Cu- and 225Ac-labeled FAPI-04 in pancreatic cancer xenograft mouse models","volume":"61","year":"2020","journal-title":"J Nucl Med"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000004073","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T20:06:00Z","timestamp":1750536360000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000004073"}},"subtitle":["Comparison With 18F-FDG PET\/CT in 22 Different Cancer Types"],"short-title":[],"issued":{"date-parts":[[2022,1,25]]},"references-count":23,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000004073","relation":{},"ISSN":["1536-0229","0363-9762"],"issn-type":[{"value":"1536-0229","type":"electronic"},{"value":"0363-9762","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1,25]]}}}